This article was originally published on GPG.com
In this edition GPG takes stock of corporate plans to return to work and tracks the most important vaccine trials. In the absence of detailed federal government direction, state, local, and private sector leaders are being left to decide how to slowly transition the country back to work. The result is a fractured and patchwork approach for our health and economy. The endgame remains a widely available, working vaccine with over 100 trials underway worldwide.